#ShionogiPharmaceutical

Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir on June 16, 2026. This achievement marks the first oral antiviral medication approved for post-exposure prophylaxis of COVID-19 globally, representing a significant advancement that accelerates the company's global expansion efforts.

Shionogi & Co., Ltd. received approval for a new drug, Nardemizin, in China, contributing to the treatment of opioid-induced constipation. The approval was granted on May 27, 2026, and further market penetration and business expansion are anticipated.

In FY2025, revenue reached 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), marking record highs.